MedPath

CRIXIVAN

CRIXIVAN (INDINAVIR SULFATE)CAPSULES

Approved
Approval ID

702727cb-3eff-425b-9573-031332849430

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 18, 2010

Manufacturers
FDA

State of Florida DOH Central Pharmacy

DUNS: 829348114

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

indinavir sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code53808-0661
Application NumberNDA020685
Product Classification
M
Marketing Category
C73594
G
Generic Name
indinavir sulfate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 18, 2010
FDA Product Classification

INGREDIENTS (7)

SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
INDINAVIR SULFATEActive
Quantity: 400 mg in 1 1
Code: 771H53976Q
Classification: ACTIM
ANHYDROUS LACTOSEInactive
Code: 3SY5LH9PMK
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CRIXIVAN - FDA Drug Approval Details